Gsk (GSK) Notes Payables (2009 - 2026)

Gsk (GSK) has 18 years of Notes Payables data on file, last reported at -$216.2 million in Q3 2026.

• For the quarter ending Q3 2026, Notes Payables changed N/A year-over-year to -$216.2 million; the trailing twelve-month figure through Sep 2026 stood at -$216.2 million (changed N/A YoY), and the FY2025 full-year result was -$4.0 billion, down 33.43% from the prior year.
• Notes Payables was -$216.2 million for Q3 2026 at Gsk, up from -$5.8 billion in the prior quarter.
• In the past five years, Notes Payables ranged from a high of -$216.2 million in Q3 2026 to a low of -$7.4 billion in Q2 2023.
• A 5-year average of -$3.9 billion and a median of -$3.9 billion in 2025 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables jumped 93.37% in 2022 and tumbled 1686.97% in 2023, its largest moves.
• Gsk's Notes Payables stood at -$4.6 billion in 2022, then climbed by 24.68% to -$3.5 billion in 2023, then gained by 13.65% to -$3.0 billion in 2024, then tumbled by 32.89% to -$4.0 billion in 2025, then soared by 94.6% to -$216.2 million in 2026.
• Per Business Quant data, the three most recent Notes Payables figures were -$216.2 million in Q3 2026, -$5.8 billion in Q2 2026, and -$6.8 billion in Q1 2026.